afimetoran
Small moleculeexperimental
Clinical trial activity
11 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 3, 2018 (NCT03634995)
Timeline
Indications
Mechanism of action
- Toll-like receptor 8INHIBITOR
TLR8 inhibitor
- Toll-like receptor 7INHIBITOR
TLR7 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(-c2[nH]c3ccc(C4CCN(CC(N)=O)CC4)cc3c2C(C)C)cn2ncnc2c1C- Mol. weight
- 444.58 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650329 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05866627 | Phase 1 | Jul 4, 2023 | Bristol-Myers Squibb |
| NCT05901714 | Phase 1 | Jun 19, 2023 | Bristol-Myers Squibb |
| NCT04895696 | Phase 2 | Jun 30, 2021 | Bristol-Myers Squibb |
| NCT04941755 | Phase 1 | Jun 25, 2021 | Bristol-Myers Squibb |
| NCT04493541 | Phase 1 | Aug 27, 2020 | Bristol-Myers Squibb |
| NCT04470778 | Phase 1 | Jul 20, 2020 | Bristol-Myers Squibb |
| NCT04269356 | Phase 1 | Feb 14, 2020 | Bristol-Myers Squibb |
| NCT04039373 | Phase 1 | Jul 22, 2019 | Bristol-Myers Squibb |
| NCT04016753 | Phase 1 | Jul 3, 2019 | Bristol-Myers Squibb |
| NCT03950960 | Phase 1 | May 17, 2019 | Bristol-Myers Squibb |
| NCT03634995 | Phase 1 | Aug 3, 2018 | Bristol-Myers Squibb |
Showing 11 of 11 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 11 | 11 | 2 | 2018 |
1 organizations
Page 1 / 1